With 2024 revenues of $1.8 billion, MSA Safety is headquartered in Cranberry Township, Pennsylvania and employs a team of more than 5,000 associates across its more than 40 international locations.

The Pittsburgh Penguins name MSA Safety, a global leader in the development, manufacture and supply of safety products and solutions, as the official road helmet partner beginning with the 2023-24 ...

MSA Safety, a developer, manufacturer and supplier of safety products, has completed the acquisition of M&C TechGroup, a manufacturer of gas analysis solutions and technologies. The deal, valued ...

Analyst Robert Mason CFA from Robert W. Baird maintained a Hold rating on MSA Safety (MSA – Research Report) and keeping the price target at $195.00. Robert Mason CFA has given his Hold rating ...

DA Davidson analyst Michael Shlisky initiated coverage of MSA Safety (MSA) with a Buy rating and $195 price target The firm also added the shares to its “Best-of-Breed Bison list.” MSA is the ...

MSA Safety said it has acquired M&C TechGroup, a supplier of gas analysis products, for about $200 million. The move was part of MSA Safety's plan to accelerate growth, which includes a focus on ...

MSA Safety (NYSE:MSA) will release its quarterly earnings report on Tuesday, 2025-04-29. Here's a brief overview for investors ahead of the announcement. Analysts anticipate MSA Safety to report ...

With 2024 revenues of $1.8 billion, MSA Safety is headquartered in Cranberry Township, Pennsylvania and employs a team of over 5,000 associates across its more than 40 international locations.

MSA Safety's Q1 2025 performance demonstrated resilience amid a challenging macroeconomic environment, with strong Detection segment growth and disciplined cost management.

MSA Safety was added to DA Davidson’s Best-of-Breed Bison list, which includes the "highest-quality companies, with wide competitive moats, strong long-term value creation potential, ...

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an ...